Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis

FASEB Journal

Volumn 25, Issue 7, 2011, Pages 2387-2398

  Zhang, Shuzhong ^a   Zheng, Mingquan ^a   Kibe, Ryoko ^a   Huang, Yunping ^a   Marrero, Luis ^a   Warren, Samantha ^a   Zieske, Arthur W ^a   Iwakuma, Tomoo ^a   Kolls, Jay K ^a   Cui, Yan ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD45.1; IL 17; IL 6; Inflammatory cytokines

Indexed keywords

CD45 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 6; PROTEIN P53; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE PRODUCTION; EFFECTOR CELL; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TH17 CELL;

ANIMALS; ANTIGENS, CD45; AUTOIMMUNITY; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; INTERLEUKIN-17; INTERLEUKIN-6; LYMPHOID TISSUE; MALE; MICE; MICE, CONGENIC; MICE, KNOCKOUT; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TH1 CELLS; TH17 CELLS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 79960199240     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-175299     Document Type: Article

References (60)

1. Levine, A. J., and Oren, M. (2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758
2. Vousden, K. H., and Lane, D. P. (2007) p53 in health and disease. Nat. Rev. 8, 275-283 (Pubitemid 46474662)
3. Tak, P. P., Zvaifler, N. J., Green, D. R., and Firestein, G. S. (2000) Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol. Today 21, 78-82 (Pubitemid 30069620)
4. Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J., and Firestein, G. S. (2002) Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. U. S. A. 99, 10025-10030 (Pubitemid 34831166)
5. Aparicio, S., and Eaves, C. J. (2009) p53: a new kingpin in the stem cell arena. Cell 138, 1060-1062
6. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J., Creyghton, M. P., van Oudenaarden, A., and Jaenisch, R. (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595-601
7. Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135
8. Utikal, J., Polo, J. M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R. M., Khalil, A., Rheinwald, J. G., and Hochedlinger, K. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145-1148
9. Marion, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., and Blasco, M. A. (2009) A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-1153
10. Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Canamero, M., Blasco, M. A., and Serrano, M. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136-1139
11. Hussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., Shields, P. G., Ham, A. J., Swenberg, J. A., Marrogi, A. J., and Harris, C. C. (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60, 3333-3337
12. Tapinos, N. I., Polihronis, M., and Moutsopoulos, H. M. (1999) Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum. 42, 1466-1472
13. Yamanishi, Y., Boyle, D. L., Pinkoski, M. J., Mahboubi, A., Lin, T., Han, Z., Zvaifler, N. J., Green, D. R., and Firestein, G. S. (2002) Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 160, 123-130 (Pubitemid 34052273)
14. Zheng, S. J., Lamhamedi-Cherradi, S. E., Wang, P., Xu, L., and Chen, Y. H. (2005) Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54, 1423-1428
15. Okuda, Y., Okuda, M., and Bernard, C. C. (2003) Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 135, 29-37
16. Yao, Q., Wang, S., Glorioso, J. C., Evans, C. H., Robbins, P. D., Ghivizzani, S. C., and Oligino, T. J. (2001) Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol. Ther. 3, 901-910 (Pubitemid 32611300)
17. Komarova, E. A., Krivokrysenko, V., Wang, K., Neznanov, N., Chernov, M. V., Komarov, P. G., Brennan, M. L., Golovkina, T. V., Rokhlin, O. W., Kuprash, D. V., Nedospasov, S. A., Hazen, S. L., Feinstein, E., and Gudkov, A. V. (2005) p53 is a suppressor of inflammatory response in mice. FASEB J. 19, 1030-1032
18. Ak, P., and Levine, A. J. (2010) p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 24, 3643-3652
19. Ghosh, S., May, M. J., and Kopp, E. B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. 16, 225-260
20. Palmer, M. T., and Weaver, C. T. (2010) Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat. Immunol. 11, 36-40
21. Pahl, H. L. (1999) Activators and target genes of Rel/NFkappaB transcription factors. Oncogene 18, 6853-6866
22. Santhanam, U., Ray, A., and Sehgal, P. B. (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. U. S. A. 88, 7605-7609
23. Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G. Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., and Karin, M. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113
24. Hirano, T., Nakajima, K., and Hibi, M. (1997) Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 8, 241-252 (Pubitemid 28202436)
25. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., and Kuchroo, V. K. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238
26. Chen, Z., and O'Shea, J. J. (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41, 87-102
27. Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., and Weaver, C. T. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132
28. McGeachy, M. J., and Cua, D. J. (2008) Th17 cell differentiation: the long and winding road. Immunity 28, 445-453 (Pubitemid 351467042)
29. Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., and Dong, C. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (Pubitemid 41541791)
30. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., and Stockinger, B. (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (Pubitemid 43214587)
31. Zhou, L., and Littman, D. R. (2009) Transcriptional regulatory networks in Th17 cell differentiation. Curr. Opin. Immunol. 21, 146-152
32. Tesmer, L. A., Lundy, S. K., Sarkar, S., and Fox, D. A. (2008) Th17 cells in human disease. Immunol. Rev. 223, 87-113
33. Harris, T. J., Grosso, J. F., Yen, H. R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., Housseau, F., Yu, H., Pardoll, D. M., and Drake, C. G. (2007) Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179, 4313-4317
34. Steinman, L. (2010) Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat. Immunol. 11, 41-44
35. Lin, J., Jin, X., Rothman, K., Lin, H. J., Tang, H., and Burke, W. (2002) Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res. 62, 376-380 (Pubitemid 34106407)
36. Lee, H., Herrmann, A., Deng, J. H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., and Yu, H. (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15, 283-293
37. Grivennikov, S. I., and Karin, M. (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19
38. Bettelli, E., Oukka, M., and Kuchroo, V. K. (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345-350
39. Diveu, C., McGeachy, M. J., and Cua, D. J. (2008) Cytokines that regulate autoimmunity. Curr. Opin. Immunol. 20, 663-668
40. Dong, C. (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8, 337-348
41. Webster, G. A., and Perkins, N. D. (1999) Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19, 3485-3495
42. Tergaonkar, V., and Perkins, N. D. (2007) p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol. Cell. 26, 158-159
43. Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti, S. M., and Turkson, J. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104, 7391-7396 (Pubitemid 47185916)
44. Puzio-Kuter, A. M., and Levine, A. J. (2009) Stem cell biology meets p53. Nat. Biotechnol. 27, 914-915
45. Danilova, N., Sakamoto, K. M., and Lin, S. (2008) p53 family in development. Mech. Dev. 125, 919-931
46. Salvador, J. M., Hollander, M. C., Nguyen, A. T., Kopp, J. B., Barisoni, L., Moore, J. K., Ashwell, J. D., and Fornace, A. J., Jr. (2002) Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16, 499-508
47. Salvador, J. M., Mittelstadt, P. R., Belova, G. I., Fornace, A. J., Jr., and Ashwell, J. D. (2005) The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat. Immunol. 6, 396-402
48. Shen, F. W., Saga, Y., Litman, G., Freeman, G., Tung, J. S., Cantor, H., and Boyse, E. A. (1985) Cloning of Ly-5 cDNA. Proc. Natl. Acad. Sci. U. S. A. 82, 7360-7363
49. Raschke, W. C., Hendricks, M., and Chen, C. M. (1995) Genetic basis of antigenic differences between three alleles of Ly5 (CD45) in mice. Immunogenetics 41, 144-147
50. Zebedee, S. L., Barritt, D., Epstein, R., and Raschke, W. C. (1991) Analysis of Ly5 chromosome 1 position using allelic differences and recombinant inbred mice. Eur. J. Immunogenet 18, 155-163
51. Do, H. T., Baars, W., Borns, K., Windhagen, A., and Schwinzer, R. (2006) The 77C->G mutation in the human CD45 (PTPRC) gene leads to increased intensity of TCR signaling in T cell lines from healthy individuals and patients with multiple sclerosis. J. Immunol. 176, 931-938 (Pubitemid 43099691)
52. Jacobsen, M., Schweer, D., Ziegler, A., Gaber, R., Schock, S., Schwinzer, R., Wonigeit, K., Lindert, R. B., Kantarci, O., Schaefer-Klein, J., Schipper, H. I., Oertel, W. H., Heidenreich, F., Weinshenker, B. G., Sommer, N., and Hemmer, B. (2000) A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat. Genet. 26, 495-499
53. Windhagen, A., Sonmez, D., Hornig-Do, H. T., Kalinowsky, A., and Schwinzer, R. (2007) Altered CD45 isoform expression in C77G carriers influences cytokine responsiveness and adhesion properties of T cells. Clin. Exp. Immunol. 150, 509-517 (Pubitemid 350098732)
54. Vang, T., Miletic, A. V., Arimura, Y., Tautz, L., Rickert, R. C., and Mustelin, T. (2008) Protein tyrosine phosphatases in autoimmunity. Annu. Rev. Immunol. 26, 29-55 (Pubitemid 351600370)
55. Majeti, R., Xu, Z., Parslow, T. G., Olson, J. L., Daikh, D. I., Killeen, N., and Weiss, A. (2000) An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103, 1059-1070 (Pubitemid 32037394)
56. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883-899
57. Karin, M. (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect. Biol. 1, a000141
58. Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., and Yu, H. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464
59. Fouser, L. A., Wright, J. F., Dunussi-Joannopoulos, K., and Collins, M. (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol. Rev. 226, 87-102
60. Bromberg, J., and Wang, T. C. (2009) Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15, 79-80